Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04504032 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)
A Phase 2 study, sponsored by Gates Medical Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 497
- Enrollment target
NCT04504032 is a Phase 2 study that was terminated before completion, run by Gates Medical Research Institute. The registered enrollment target is 497 participants.
The verdict
NCT04504032, a Phase 2 study, was terminated before completion, sponsored by Gates Medical Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 497 participants
- Enrollment target
Study Summary
The purpose of this study is to assess safety and clinical efficacy of rivaroxaban in people with mild Coronavirus Disease 2019 who are at increased risk of disease progression.
Interventions
- DRUG Placebo
- DRUG Rivaroxaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 497 participants |
| Start Date | 2020-09-02 |
| Est. Completion | 2021-03-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04504032
The ClinicalTrials.gov registry entry for NCT04504032 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 497 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gates Medical Research Institute, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04504032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04504032 about?
NCT04504032 is a clinical study titled "A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)". The purpose of this study is to assess safety and clinical efficacy of rivaroxaban in people with mild Coronavirus Disease 2019 who are at increased risk of disease progression.
What is the current status of trial NCT04504032?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 497 participants. The study started on 2020-09-02. Estimated completion is 2021-03-29.
What interventions are being tested in trial NCT04504032?
The interventions under investigation include: Placebo (DRUG), Rivaroxaban (DRUG).
Who is sponsoring clinical trial NCT04504032?
This trial is sponsored by Gates Medical Research Institute, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.